statistiche ricercatore

Continente	#
NA - Nord America	736
AS - Asia	596
EU - Europa	365
AF - Africa	42
SA - Sud America	30
Continente sconosciuto - Info sul continente non disponibili	23
OC - Oceania	3
Totale	1.795

Nazione	#
US - Stati Uniti d'America	725
VN - Vietnam	194
CN - Cina	147
SG - Singapore	131
GB - Regno Unito	103
DE - Germania	66
HK - Hong Kong	55
IT - Italia	40
SE - Svezia	34
IN - India	24
FR - Francia	22
RU - Federazione Russa	22
BR - Brasile	20
IE - Irlanda	18
UA - Ucraina	18
CI - Costa d'Avorio	14
JP - Giappone	11
NG - Nigeria	10
NL - Olanda	10
ZA - Sudafrica	10
KR - Corea	9
CA - Canada	8
FI - Finlandia	7
BE - Belgio	5
EE - Estonia	5
AR - Argentina	4
CH - Svizzera	4
JO - Giordania	4
AU - Australia	3
EC - Ecuador	3
IR - Iran	3
LT - Lituania	3
TG - Togo	3
TR - Turchia	3
BD - Bangladesh	2
CO - Colombia	2
GR - Grecia	2
ID - Indonesia	2
PH - Filippine	2
PL - Polonia	2
SA - Arabia Saudita	2
TH - Thailandia	2
TW - Taiwan	2
BG - Bulgaria	1
CR - Costa Rica	1
EG - Egitto	1
IQ - Iraq	1
KE - Kenya	1
MA - Marocco	1
MD - Moldavia	1
MX - Messico	1
PK - Pakistan	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
SO - Somalia	1
SV - El Salvador	1
TN - Tunisia	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.772

Nome	#
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies	289
Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature	214
Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study	205
Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).	204
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database	199
Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy	166
Triptans and serious cardiovascular events: possible safety signals from the FDA Adverse Event Reporting System database	162
Pattern of Triptan Use in a Sample of the Italian General Population	131
Ticlopidine’s safety profile: a case/non case study on the basis of the spontaneous ADR reporting in Italy.	117
Factors Influencing the Disproportional Association Between Triptans and Cerebrovascular Events Within the FDA_AERS Database: Causal Association or Reporting Bias?	108
Totale	1.795

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	133	0	0	0	5	15	6	2	9	6	5	44	41
2022/2023	225	23	33	14	25	22	19	4	10	44	7	15	9
2023/2024	41	9	8	2	12	0	3	1	1	1	1	2	1
2024/2025	232	13	19	14	13	54	22	10	10	0	10	8	59
2025/2026	599	48	43	54	41	63	24	124	18	99	53	20	12
2026/2027	94	6	21	33	34	0	0	0	0	0	0	0	0
Totale													1.795

CRIS Current Research Information System